Stifel Financial Corp Purchases 9,341 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Stifel Financial Corp lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,032 shares of the medical equipment provider's stock after buying an additional 9,341 shares during the period. Stifel Financial Corp's holdings in Zimmer Biomet were worth $10,144,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Franklin Resources Inc. raised its position in Zimmer Biomet by 398.7% in the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. Norges Bank acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $216,223,000. Dodge & Cox increased its holdings in shares of Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after buying an additional 2,044,645 shares in the last quarter. Sound Shore Management Inc. CT acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth approximately $81,447,000. Finally, FMR LLC increased its holdings in shares of Zimmer Biomet by 91.6% during the fourth quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock worth $151,897,000 after buying an additional 687,675 shares in the last quarter. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.95% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on ZBH shares. Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Royal Bank of Canada lowered their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Trading Down 1.1 %

Shares of ZBH traded down $1.16 during trading hours on Thursday, reaching $101.89. The stock had a trading volume of 1,400,717 shares, compared to its average volume of 1,665,968. The company has a market cap of $20.16 billion, a P/E ratio of 22.90, a P/E/G ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a 52 week low of $93.10 and a 52 week high of $123.96. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average of $105.72 and a 200 day moving average of $106.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 earnings per share. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.94%. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.